Skin cancer biopsy rates among providers, top dermatology stories

Dermatologists performed the fewest number of biopsies to diagnose one skin cancer compared with other types of clinicians, according to researchers from University of Wisconsin-Madison and Mayo Clinic, in the top Healio Dermatology story last week.

In another top story, researchers explored infliximab dosing regimens for optimal disease control in hidradenitis suppurativa. They found that 67% of patients achieved stable dosing at a scheduled 10 mg/kg every 6 to 8 weeks.

Continue reading for more top stories from last week.

 

Dermatologists perform fewest biopsies to diagnose skin cancer

The number needed to biopsy rate was the lowest for dermatology MDs, followed by dermatology advanced practice professionals, non-dermatology PCPs and other non-dermatology physicians. Read more.

 

Remicade 10 mg reasonable starting dose for hidradenitis suppurativa

For most patients with hidradenitis suppurativa, a dosage of at least 10 mg/kg of Remicade every 8 weeks will optimize treatment. Read more.

 

Tremfya shows efficacy for palmoplantar pustulosis

Tremfya at 100 mg and 200 mg doses showed therapeutic and quality-of-life improvement through week 52 in a phase 3 clinical trial of Japanese patients with moderate to severe palmoplantar pustulosis. Read more.

 

Elderly patients with nonmelanoma skin cancer more likely to go untreated

Patients with nonmelanoma skin cancer aged 85 years or older had significantly higher odds of being untreated. Read more.

 

Early ustekinumab levels may be useful in psoriasis treatment strategy

Researchers found a statistically significant association between early ustekinumab levels and 6-month Psoriasis Area and Severity Index-75 response in patients taking the drug. Read more.

Dermatologists performed the fewest number of biopsies to diagnose one skin cancer compared with other types of clinicians, according to researchers from University of Wisconsin-Madison and Mayo Clinic, in the top Healio Dermatology story last week.

In another top story, researchers explored infliximab dosing regimens for optimal disease control in hidradenitis suppurativa. They found that 67% of patients achieved stable dosing at a scheduled 10 mg/kg every 6 to 8 weeks.

Continue reading for more top stories from last week.

 

Dermatologists perform fewest biopsies to diagnose skin cancer

The number needed to biopsy rate was the lowest for dermatology MDs, followed by dermatology advanced practice professionals, non-dermatology PCPs and other non-dermatology physicians. Read more.

 

Remicade 10 mg reasonable starting dose for hidradenitis suppurativa

For most patients with hidradenitis suppurativa, a dosage of at least 10 mg/kg of Remicade every 8 weeks will optimize treatment. Read more.

 

Tremfya shows efficacy for palmoplantar pustulosis

Tremfya at 100 mg and 200 mg doses showed therapeutic and quality-of-life improvement through week 52 in a phase 3 clinical trial of Japanese patients with moderate to severe palmoplantar pustulosis. Read more.

 

Elderly patients with nonmelanoma skin cancer more likely to go untreated

Patients with nonmelanoma skin cancer aged 85 years or older had significantly higher odds of being untreated. Read more.

 

Early ustekinumab levels may be useful in psoriasis treatment strategy

Researchers found a statistically significant association between early ustekinumab levels and 6-month Psoriasis Area and Severity Index-75 response in patients taking the drug. Read more.